6533b7d5fe1ef96bd1263bb8
RESEARCH PRODUCT
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
Rene SwaninkLambert BusquePatricia Martin RegueiraSatu MustjokiRebecca B. KlisovicDominik WolfDominik WolfJoaquin Martinez-lopezJuan Carlos Hernández-boludaKimmo PorkkaJeffrey H. Liptonsubject
OncologyCancer Researchmedicine.medical_specialty03 medical and health sciences0302 clinical medicineText mininghemic and lymphatic diseasesInternal medicinemedicineDose escalationIn patientbusiness.industryMyeloid leukemiaHematologymedicine.diseaserespiratory tract diseases3. Good healthDasatinibOncology030220 oncology & carcinogenesisNivolumabbusinessTyrosine kinase030215 immunologyChronic myelogenous leukemiamedicine.drugdescription
Although treatment with tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes for the majority of patients with chronic myeloid leukemia (CML), approximately 20–30% will require a ch...
year | journal | country | edition | language |
---|---|---|---|---|
2021-03-02 | Leukemia & Lymphoma |